About ZYMERON CORPORATION
Zymeron is a preclinical pharmaceutical startup focused on developing myeloprotective and osteoprotective drugs to preserve the health of the osteomyeloid structure and improve the quality of life for cancer patients undergoing chemoradiotherapy.
Development of myeloprotective and osteoprotective drugsDrug delivery and formulation technologiesProprietary peptide drug conjugate (PDC) for cytoprotective molecule deliveryReformulation of poorly soluble drugs into injectables
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| ZYMERON DHA SBIR PHASE I H231-004-0023 NOVEL AEROSOL THERAPY FOR IMMEDIATE AND SUSTAINED ARDS MANAGEMENT | Department of Defense | $250K | |
| Federal contract award | Department of Health and Human Services | $1.5M | |
| RAPID POINT OF CARE TESTS TO SIMULTANEOUSLY QUANTIFY ANTI-TB DRUGS IN BLOOD. | Department of Health and Human Services | $1.3M | |
| Federal contract award | Department of Health and Human Services | $400K | |
| Federal contract award | Department of Defense | $225K |
Is this your company?
Claim ZYMERON CORPORATION to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim ZYMERON CORPORATION & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.